Showcasing a Groundbreaking Possibility for Alertgy's Non-Invasive Propriety Sensor Technology

The current COVID-19 pandemic has highlighted the need for rapid development of reliable tests for emerging dangerous pathogens, especially those that are airborne. Current molecular biology tests, such as the real-time quantitative, polymerase chain reaction (RT-qPCR) and a newly developed antigen tests are widely used to detect SARS-CoV-2. These methods require months to develop as they must be generated and produced on an exceptionally large scale. Furthermore, they require expensive reagents, additional instruments, technical expertise, standardization protocols, and, in the case of RT-qPCR, require long turnover times that greatly hinder therapeutic and preventative strategies. Now more than ever, it is clear that these present a large percentage of false positive and negative results, significantly hampering the fight against the epidemic and negatively impact clinical outcomes.

Alertgy’s proposed viral particle detection method will afford several significant advantages in detecting infected individuals during a pandemic. It is non-invasive, inexpensive, rapid, requires no reagents or swabs, and eliminates operator error. The provision of new instrumentation for the non-invasive detection of SARS-CoV-2 and other respiratory viruses will represent a significant contribution to both fields of dielectric spectroscopy and viral detection/diagnosis. Alertgy’s approach plans to revolutionize the diagnostic testing industry, helping aid and preventing future pandemics that may arise.